Welcome to STN International! Enter x:x

LOGINID:ssspta1125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Mar 24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS 32	Apr 11	Display formats in DGENE enhanced
NEWS 33	Apr 14	MEDLINE Reload

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2003 HIGHEST RN 503084-53-5
DICTIONARY FILE UPDATES: 15 APR 2003 HIGHEST RN 503084-53-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s name
L1 4 NAME

=> d l1 4

L1 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 50903-99-6 REGISTRY
CN L-Ornithine, N5-[imino(nitroamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **L-NAME**
CN **L-NAME**
CN N-Nitro-L-arginine methyl ester
CN N.omega.-Nitro-L-arginine methyl ester
CN N.omega.-Nitro-L-arginine methyl ester
CN **NAME**
CN NG-Nitro-L-arginine Me ester
CN NG-Nitro-L-arginine methyl ester
FS STEREOSEARCH
DR 162715-84-6, 126265-24-5, 189639-12-1
MF C7 H15 N5 O4

CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CIN, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



514/554,588

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1368 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1373 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s mifepristone
L2 5 MIFEPRISTONE

=> d l2 5

L2 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 84371-65-3 REGISTRY
CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 17.beta.-Hydroxy-11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one
CN CDB 2477
CN Mifegyne
CN Mifeprex
CN **Mifepristone**
CN Mifestone
CN R 38486
CN RU 38486
CN RU 486
CN RU 486-6
CN RU486
FS STEREOSEARCH
DR 122742-25-0, 83203-42-3
MF C29 H35 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, GMELIN*, HSDB*, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



514 1171

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1811 REFERENCES IN FILE CA (1962 TO DATE)
59 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1813 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> s org31710
L3            0 ORG31710

=> s org 3171-
            546 ORG
            590 3171
L4            0 ORG 3171-
                (ORG(W)3171)

=> s org 31710
            546 ORG
             20 31710
L5            1 ORG 31710
                (ORG(W)31710)

=> s l5
            546 ORG
             20 31710
L6            1 ORG 31710
                (ORG(W)31710)

=> s l5
            546 ORG
             20 31710
L7            1 ORG 31710
                (ORG(W)31710)

=> d l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   118968-41-5  REGISTRY
CN   Spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one, 11-[4-
     (dimethylamino)phenyl]-4',5'-dihydro-6-methyl-,
     (6.beta.,11.beta.,17.beta.)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Spiro[17H-cyclopenta[a]phenanthrene-17,2'(3'H)-furan],
     spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one deriv.
OTHER NAMES:
CN   Org 31710
FS   STEREOSEARCH
```

MF C30 H39 N O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMINFORMRX, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

33 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> s org 33628
           546 ORG
            18 33628
L8           1 ORG 33628
                (ORG(W)33628)

=> d 18

L8   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   155768-17-5  REGISTRY
CN   19,24-Dinorchola-4,9,20-trien-3-one, 11-(4-acetylphenyl)-17,23-epoxy-,
     (11.beta.,17.alpha.)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Spiro[17H-cyclopenta[a]phenanthrene-17,2'(3'H)-furan],
     19,24-dinorchola-4,9,20-trien-3-one deriv.
OTHER NAMES:
CN   Org 33628
FS   STEREOSEARCH
MF   C30 H34 O3
SR   CA
LC   STN Files:  BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, TOXCENTER, USPATFULL

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1962 TO DATE)
13 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> s j 867
         69368 J
          1170 867
L9           1 J 867
                 (J(W)867)

=> d l9

L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   199396-76-4  REGISTRY
CN   Benzaldehyde, 4-[(11.beta.,17.beta.)-17-methoxy-17-(methoxymethyl)-3-
     oxoestra-4,9-dien-11-yl]-, 1-oxime, [C(E)]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Asoprisnil
CN   J 867
FS   STEREOSEARCH
DR   222732-64-1
MF   C28 H35 N O4
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, CASREACT, DRUGUPDATES, PHAR,
       SYNTHLINE, TOXCENTER, USPATFULL

Absolute stereochemistry.  Rotation (+).
Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1962 TO DATE)
15 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s cdb 2914
57 CDB
534 2914
L10 1 CDB 2914
(CDB(W)2914)

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 126784-99-4 REGISTRY
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **CDB 2914**
CN RTI 3021-012
FS STEREOSEARCH
MF C30 H37 N O4
SR CA
LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, MEDLINE, PROMT, SYNTHLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23 REFERENCES IN FILE CA (1962 TO DATE)
23 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s zk 137316
248 ZK
2 137316
L11 1 ZK 137316
(ZK(W)137316)

=> d l11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 198907-45-8 REGISTRY
CN **ZK 137316 (9CI)** (CA INDEX NAME)
ENTE A hormonal steroid; an antiprogestin
MF Unspecified

```
CI   MAN
SR   CA
LC   STN Files:   BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
              12 REFERENCES IN FILE CA (1962 TO DATE)
              12 REFERENCES IN FILE CAPLUS (1962 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      94.74      94.95

FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Apr 2003  VOL 138 ISS 16
FILE LAST UPDATED: 15 Apr 2003  (20030415/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s nitric oxide synthase
        130512 NITRIC
       1369614 OXIDE
         70286 SYNTHASE
L12      21216 NITRIC OXIDE SYNTHASE
                (NITRIC(W)OXIDE(W)SYNTHASE)

=> d his

     (FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003)

     FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
L1             4 S NAME
L2             5 S MIFEPRISTONE
L3             0 S ORG31710
L4             0 S ORG 3171-
L5             1 S ORG 31710
L6             1 S L5
L7             1 S L5
L8             1 S ORG 33628
L9             1 S J 867
L10            1 S CDB 2914
L11            1 S ZK 137316

     FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
```

```
L12       21216 S NITRIC OXIDE SYNTHASE

=> s l1
L13        1379 L1

=> e fertility
E1           52     FERTILITIES/BI
E2            1     FERTILITTY/BI
E3        27611 --> FERTILITY/BI
E4            1     FERTILITYARE/BI
E5            1     FERTILITYDISTURBED/BI
E6            1     FERTILITZER/BI
E7            3     FERTILIY/BI
E8            8     FERTILIZ/BI
E9            4     FERTILIZA/BI
E10         174     FERTILIZABILITY/BI
E11          82     FERTILIZABLE/BI
E12           1     FERTILIZACION/BI

=> s e3
L14       27611 FERTILITY/BI

=> s l14 and l13
L15           6 L14 AND L13

=> d l15 1-6

L15  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:869589  CAPLUS
DN   137:346927
TI   Implantation rates after in vitro fertilization, and treatment of
     infertility and early pregnancy loss with a nitric oxide donor or
     substrate alone or in combination with progesterone, and a method for
     contraception with nitric oxide inhibitors in combination with
     antiprogestins or other agents
IN   Chwalisz, Krzysztof; Garfield, Robert E.
PA   Germany
SO   U.S. Pat. Appl. Publ., 15 pp., Division of U.S. Ser. No. 162,446.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   US 2002169205      A1    20021114      US 2002-43232    20020114
PRAI US 1998-162446     A3    19980929

L15  ANSWER 2 OF 6  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:256294  CAPLUS
DN   136:295093
TI   Preparation of peptides as melanocortin receptor ligands
IN   Ebetino, Frank Hallock; Mazur, Adam W.; Hayes, Jeffrey Charles; Wang,
     Feng; Solinsky, Mark Gregory; Colson, Anny-odile; Lin, Qishen
PA   Procter & Gamble Company, USA
SO   PCT Int. Appl., 123 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002026774      A2    20020404      WO 2001-US30051  20010926
```

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-235858P P 20000927
OS MARPAT 136:295093

L15 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2002:128843 CAPLUS
DN 137:199357
TI Growth and **fertility** rates in the offspring of pregnant rats treated with L-.omega. nitro-L-arginine methyl ester (L-NAME), a nitric oxide inhibitor
AU Witlin, Andrea G.; Gangula, Pandu R. R.; Thompson, Mindy L.; Yallampalli, Chandra
CS Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Division of Reproductive Sciences, The University of Texas Medical Branch at Galveston, Galveston, TX, 77555-1062, USA
SO American Journal of Obstetrics and Gynecology (2002), 186(1), 89-93
CODEN: AJOGAH; ISSN: 0002-9378
PB Mosby, Inc.
DT Journal
LA English
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2000:436227 CAPLUS
DN 133:291057
TI Reduction in libido and **fertility** of male rats by administration of the nitric oxide (NO) synthase inhibitor N-nitro-L-arginine methyl ester
AU Ratnasooriya, W. D.; Dharmasiri, M. G.; Wadsworth, R. M.
CS Department of Zoology, University of Colombo, Colombo, 3, Sri Lanka
SO International Journal of Andrology (2000), 23(3), 187-191
CODEN: IJANDP; ISSN: 0105-6263
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1999:203927 CAPLUS
DN 131:39874
TI Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat
AU Chwalisz, Kristof; Winterhager, Elke; Thienel, Thomas; Garfield, Robert E.
CS Research Laboratories of Schering AG, Berlin, 13342, Germany
SO Human Reproduction (1999), 14(2), 542-552
CODEN: HUREEE; ISSN: 0268-1161
PB Oxford University Press
DT Journal
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1994:289794 CAPLUS
DN 120:289794
TI Effects of nitric oxide-related agents on rat testicular function
AU Adams, Michael L.; Meyer, Edward R.; Sewing, Bryan N.; Cicero, Theodore J.
CS Sch. Med., Washington Univ., St. Louis, MO, USA
SO Journal of Pharmacology and Experimental Therapeutics (1994), 269(1), 230-7
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

=> d l15 6 all

L15 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1994:289794 CAPLUS
DN 120:289794
TI Effects of nitric oxide-related agents on rat testicular function
AU Adams, Michael L.; Meyer, Edward R.; Sewing, Bryan N.; Cicero, Theodore J.
CS Sch. Med., Washington Univ., St. Louis, MO, USA
SO Journal of Pharmacology and Experimental Therapeutics (1994), 269(1), 230-7
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English
CC 1-8 (Pharmacology)
Section cross-reference(s): 2
AB The effects of nitric oxide (NO)-related agents on testicular function were examd. in male rats with measurements of serum LH, serum testosterone, testicular interstitial fluid (TIF) testosterone, and TIF vols. Serum and TIF testosterone levels and LH secretion were significantly decreased by the NO donor, isosorbide dinitrate (ISDN), and the NO synthase (NOS) substrate, L-arginine Me ester, a source for the endogenous prodn. of NO. The effects of ISDN on TIF vols. were inconsistent, but L-arginine Me ester decreased TIF formation in a dose-dependent manner. In addn., ISDN dose-dependently suppressed testosterone secretion stimulated by human chorionic gonadotropin treatment, suggesting that the effects on testosterone secretion were independent of changes in secretion of the endogenous gonadotropin LH. ISDN, L-arginine Me ester, and the endogenous NOS substrate L-arginine completely blocked testosterone secretion stimulated by the NOS inhibitor NG-nitro-L-arginine Me ester (NAME), whereas the relatively inactive NOS substrate, D-arginine, only partially blocked NAME-stimulated testosterone secretion. Hydralazine and nicardipine, two vasodilators that do not exhibit prominent NO-related effects, also blocked basal testosterone secretion and testosterone secretion stimulated by the vasoconstrictor NAME. These results suggest that (1) NO suppresses a major regulatory aspect of testicular function, testosterone secretion, (2) the stimulatory effects of the NOS inhibitor NAME on testosterone secretion are caused by NOS inhibition and a decrease in NO prodn., (3) the vasoactive effects of NO and NOS inhibitors, rather than direct steroidogenic effects, may mediate these effects on testicular function, and (4) arginine-NOS-NO pathways may play an important role in male reproductive endocrine function and **fertility**.
ST nitric oxide related agent testicular function
IT Testis
(function, nitric oxide-related agents effect on)
IT Vasodilators
(nitric oxide-related agents as, testicular function response to)
IT 10102-43-9, Nitric oxide, biological studies

RL: BIOL (Biological study)
(agents effect on, testicular function response to)
IT 125978-95-2, Nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor, testicular function response to, nitric oxide role in)
IT 58-22-0, Testosterone 9002-67-9, LH
RL: BIOL (Biological study)
(secretion, nitric oxide-related agents effect on)
IT 74-79-3, L-Arginine, biological studies 87-33-2, Isosorbide dinitrate
157-06-2, D-Arginine 2577-94-8, L-Arginine methyl ester
50903-99-6
RL: BIOL (Biological study)
(testicular function response to, nitric oxide role in)

=> d his

(FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003)

FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
L1 4 S NAME
L2 5 S MIFEPRISTONE
L3 0 S ORG31710
L4 0 S ORG 3171-
L5 1 S ORG 31710
L6 1 S L5
L7 1 S L5
L8 1 S ORG 33628
L9 1 S J 867
L10 1 S CDB 2914
L11 1 S ZK 137316

FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
L12 21216 S NITRIC OXIDE SYNTHASE
L13 1379 S L1
E FERTILITY
L14 27611 S E3
L15 6 S L14 AND L13

=> s l14 and l12
L16 23 L14 AND L12

=> s l16 not l15
L17 18 L16 NOT L15

=> d l17 1-18

L17 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2002:508556 CAPLUS
DN 137:195831
TI Deletion of exon 6 of the neuronal **nitric oxide synthase** gene in mice results in hypogonadism and infertility
AU Gyurko, Robert; Leupen, Sarah; Huang, Paul L.
CS Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA
SO Endocrinology (2002), 143(7), 2767-2774
CODEN: ENDOAO; ISSN: 0013-7227
PB Endocrine Society
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2002:294227 CAPLUS
DN 136:315023
TI Polydithiocarbamate-containing nontargeting macromolecules for therapeutic and diagnostic applications
IN Lai, Ching-san
PA USA
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 899,087, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002045573	A1	20020418	US 1999-409645	19991001
	CN 1230178	A	19990929	CN 1997-197797	19970828
	KR 2000035992	A	20000626	KR 1999-7001945	19990309
PRAI	US 1996-25867P	P	19960910		
	US 1997-899087	B2	19970723		
	US 1996-25867	A	19960910		

OS MARPAT 136:315023

L17 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2002:179993 CAPLUS
DN 137:246002
TI **Nitric oxide synthase** and the function of sperm in varicocele patients
AU Zheng, Hang; Zheng, Xinmin; Li, Shiwen
CS Center of Urology and Andrology, Second Affiliated Hospital, Wuhan university, Wuhan, 430071, Peop. Rep. China
SO Zhongguo Nankexue Zazhi (2001), 15(4), 239-241
CODEN: ZNZHA4; ISSN: 1008-0848
PB Shanghai Dier Yike Daxue
DT Journal
LA Chinese

L17 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2001:577412 CAPLUS
DN 136:303868
TI L-arginine, the substrate of **nitric oxide synthase**, inhibits **fertility** of male rats
AU Ratnasooriya, W. D.; Dharmasiri, M. G.
CS Department of Zoology, University of Colombo, Colombo, 3, Sri Lanka
SO Asian Journal of Andrology (2001), 3(2), 97-103
CODEN: ASJAF8; ISSN: 1008-682X
PB Science Press
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2001:121007 CAPLUS
DN 135:75223
TI Expression of endothelial **nitric oxide synthase** in the Sertoli cells of men with infertility of various causes
AU Fujisawa, M.; Yamanaka, K.; Tanaka, H.; Tanaka, H.; Okada, H.; Arakawa, S.; Kamidono, S.
CS Department of Urology, Kobe University School of Medicine, Kobe, Japan

SO BJU International (2001), 87(1), 85-88
CODEN: BJINFO; ISSN: 1464-4096
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2001:11841 CAPLUS
DN 134:113686
TI Nitric oxide in human sperm
AU Lewis, Sheena E. M.
CS Department of Obstetrics and Gynaecology, The Queen's University of Belfast, Belfast, UK
SO Assisted Reproduction Reviews (1998), 8(2), 58-64
CODEN: AEPEEJ; ISSN: 1051-2446
PB Decker Periodicals
DT Journal
LA English
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2000:774625 CAPLUS
DN 134:40627
TI Inducible **nitric oxide synthase** in the rat testis: Evidence for potential roles in both normal function and inflammation-mediated infertility
AU O'Bryan, Moira K.; Schlatt, Stefan; Gerdprasert, Orapin; Phillips, David J.; de Kretser, David; Hedger, Mark P.
CS Monash Inst. Reproduction and Development, Monash Univ., Clayton, 3168, Australia
SO Biology of Reproduction (2000), 63(5), 1285-1293
CODEN: BIREBV; ISSN: 0006-3363
PB Society for the Study of Reproduction
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 2000:311908 CAPLUS
DN 133:87259
TI Activation of platelet-activating factor (PAF) receptor stimulates nitric oxide (NO) release via protein kinase C-.alpha. in HEC-1B human endometrial epithelial cell line
AU Dearn, Sharon; Rahman, Mabhub; Lewis, Aurelia; Ahmed, Zahra; Eggo, Margaret C.; Ahmed, Asif
CS Department of Reproductive and Vascular Biology, Division of Reproductive and Child Health, Birmingham Women's Hospital, University of Birmingham, Birmingham, B15 2TG, UK
SO Molecular Medicine (New York) (2000), 6(1), 37-49
CODEN: MOMEF3; ISSN: 1076-1551
PB Johns Hopkins University Press
DT Journal
LA English
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1999:819234 CAPLUS

DN 132:59191
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San; Vassilev, Vassil
PA Medinox, Inc., USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966918	A1	19991229	WO 1999-US14237	19990622
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6093743	A	20000725	US 1998-103639	19980623
	CA 2335858	AA	19991229	CA 1999-2335858	19990622
	AU 9947119	A1	20000110	AU 1999-47119	19990622
	EP 1089723	A1	20010411	EP 1999-930617	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518441	T2	20020625	JP 2000-555604	19990622
	US 6316502	B1	20011113	US 2000-565666	20000505
PRAI	US 1998-103639	A2	19980623		
	WO 1999-US14237	W	19990622		

OS MARPAT 132:59191
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1999:678176 CAPLUS
DN 132:48170
TI Reproductive Function in Female Mice Lacking the Gene for Endothelial **Nitric Oxide Synthase**
AU Drazen, Deborah L.; Klein, Sabra L.; Burnett, Arthur L.; Wallach, Edward E.; Crone, Julie K.; Huang, Paul L.; Nelson, Randy J.
CS Behavioral Neuroendocrinology Group, Departments of Psychology and Neuroscience, Johns Hopkins University, Baltimore, MD, 21218, USA
SO Nitric Oxide (1999), 3(5), 366-374
CODEN: NIOXF5; ISSN: 1089-8603
PB Academic Press
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1999:447987 CAPLUS
DN 131:255383
TI Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene
AU Noiri, Eisei; Dickman, Kate; Miller, Frederick; Romanov, Galina; Romanov, Victor I.; Shaw, Robert; Chambers, Ann F.; Rittling, Susan R.; Denhardt, David T.; Goligorsky, Michael S.
CS Department of Medicine, The University of Tokyo, Tokyo, Japan

SO Kidney International (1999), 56(1), 74-82
CODEN: KDYIA5; ISSN: 0085-2538
PB Blackwell Science, Inc.
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:788750 CAPLUS
DN 130:33045
TI Method using a nitric oxide scavenger for in vivo reduction of nitric oxide levels, and compositions useful therefor
IN Lai, Ching-San
PA MCW Research Foundation, USA
SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 554,196.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847004	A	19981208	US 1996-767125	19961209
	US 5756540	A	19980526	US 1995-459518	19950602
	US 5741815	A	19980421	US 1995-554196	19951106
	US 6469057	B1	20021022	US 2000-672140	20000927
	US 2003040511	A1	20030227	US 2002-267528	20021008
PRAI	US 1995-459518	A2	19950602		
	US 1995-554196	A2	19951106		
	US 1996-767125	A2	19961209		
	US 1997-863059	B2	19970523		
	US 2000-672140	A3	20000927		

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:755828 CAPLUS
DN 130:151457
TI Impaired ovulation in mice with targeted deletion of the neuronal isoform of **nitric oxide synthase**
AU Klein, Sabra L.; Carnovale, David; Burnett, Arthur L.; Wallach, Edward E.; Zacur, Howard A.; Crone, Julie K.; Dawson, Valina L.; Nelson, Randy J.; Dawson, Ted M.
CS Behavioral Neuroendocrinology Group, Department of Psychology, Johns Hopkins University, Baltimore, MD, USA
SO Molecular Medicine (New York) (1998), 4(10), 658-664
CODEN: MOMEF3; ISSN: 1076-1551
PB Springer-Verlag New York Inc.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:370682 CAPLUS
DN 129:118187
TI Chronic blockade of **nitric oxide-synthase** and endothelin receptors during pregnancy in the rat: effect on pregnancy outcome
AU Wight, Edward; Kung, Christoph F.; Moreau, Pierre; Takase, Hiroyuki; Luscher, Thomas F.
CS Department of Obstetrics and Gynecology, University Hospital Zurich,

Zurich, CH-8091, Switz.
SO Journal of the Society for Gynecologic Investigation (1998), 5(3), 132-139
CODEN: JSGIED; ISSN: 1071-5576
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:180841 CAPLUS
DN 128:239488
TI Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
IN Lai, Ching-San
PA Medinox, Inc., USA; Lai, Ching-San
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811066	A1	19980319	WO 1997-US15324	19970828
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741725	A1	19980402	AU 1997-41725	19970828
	AU 746790	B2	20020502		
	EP 927159	A1	19990707	EP 1997-939694	19970828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1230178	A	19990929	CN 1997-197797	19970828
	JP 2002511837	T2	20020416	JP 1998-513688	19970828
	KR 2000035992	A	20000626	KR 1999-7001945	19990309
PRAI	US 1996-25867P	P	19960910		
	US 1997-899087	A2	19970723		
	US 1996-25867	A	19960910		
	WO 1997-US15324	W	19970828		

OS MARPAT 128:239488
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1997:745947 CAPLUS
DN 128:19047
TI Improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor
IN Chwalsz, Krzysztof; Garfield, Robert E.
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9741866 A1 19971113 WO 1997-EP2371 19970507
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 6040340 A 20000321 US 1996-646518 19960507
AU 9728947 A1 19971126 AU 1997-28947 19970507
EP 906105 A1 19990407 EP 1997-923032 19970507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
CN 1218402 A 19990602 CN 1997-194452 19970507
BR 9708980 A 19990803 BR 1997-8980 19970507
JP 2000510462 T2 20000815 JP 1997-539553 19970507
NO 9805204 A 19990106 NO 1998-5204 19981106
KR 2000010833 A 20000225 KR 1998-708974 19981106
PRAI US 1996-646518 A 19960507
WO 1997-EP2371 W 19970507

L17 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1996:324262 CAPLUS
DN 125:54130
TI The immunohistochemical localization of **nitric oxide synthase** (NOS) in the human male reproductive tract and in spermatozoa, suggests a possible role for nitric oxide in spermatogenesis and sperm maturation and an association with subfertility.
AU Zini, Armand; O'Bryan, Moira K.; Magid, Margaret; Schlegel, Peter N.
CS Department Urology, James Buchanan Brady Foundation, New York, NY, 10021, USA
SO Portland Press Proceedings (1996), 10(Biology of Nitric Oxide Part 5), 19
CODEN: POPPEF; ISSN: 0966-4068
PB Portland Press
DT Journal
LA English

L17 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1995:688648 CAPLUS
DN 123:80417
TI **Nitric oxide synthase** in the rat fallopian tube is regulated during the estrous cycle
AU Bryant, C. E.; Tomlinson, A.; Mitchell, J. A.; Thiemermann, C.; Willoughby, D. A.
CS Dep. Exp. Pathol., Med. Coll. St. Bartholomew's Hosp., London, EC1M 6BQ, UK
SO Journal of Endocrinology (1995), 146(1), 149-57
CODEN: JOENAK; ISSN: 0022-0795
PB Journal of Endocrinology
DT Journal
LA English

=> d l17 12-18 all

L17 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:788750 CAPLUS
DN 130:33045
TI Method using a nitric oxide scavenger for in vivo reduction of nitric oxide levels, and compositions useful therefor
IN Lai, Ching-San

PA MCW Research Foundation, USA
SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 554,196.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01N037-18
NCL 514599000
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847004	A	19981208	US 1996-767125	19961209
	US 5756540	A	19980526	US 1995-459518	19950602
	US 5741815	A	19980421	US 1995-554196	19951106
	US 6469057	B1	20021022	US 2000-672140	20000927
	US 2003040511	A1	20030227	US 2002-267528	20021008
PRAI	US 1995-459518	A2	19950602		
	US 1995-554196	A2	19951106		
	US 1996-767125	A2	19961209		
	US 1997-863059	B2	19970523		
	US 2000-672140	A3	20000927		

AB Methods are provided for the in vivo redn. of nitric oxide levels in a mammalian subject. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide prodn. is inhibited), the present invention employs a scavenging approach whereby overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complex renders the nitric oxide harmless, and is eventually excreted in the urine of the host. An exemplary nitric oxide scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. This complex binds to .NO, forming a stable, water-sol. NO-contg. complex having a characteristic three-line spectrum (indicative of a mononitrosyl-Fe complex) which can readily be detected at ambient temps. by EPR spectroscopy. The invention relates to methods for reducing in vivo levels of .NO as a means of treating subjects afflicted with inflammatory and/or infectious disease. Nitric oxide scavengers are administered to a host in need of such treatment; these scavengers interact with in vivo produced .NO, forming a stable NO-contg. complex. The NO-contg. complex is then filtered through the kidneys, concd. in the urine, and eventually excreted by the subject, thereby reducing in vivo .NO levels.

ST nitric oxide scavenger therapeutic

IT AIDS (disease)
(AIDS dementia complex, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Mental disorder
(AIDS dementia, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Intestine, disease
(Crohn's, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Nervous system
(Huntington's chorea, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Respiratory distress syndrome
(adult, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Transplant rejection
(allotransplant, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Nervous system

(amyotrophic lateral sclerosis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Nervous system
Nervous system
(central, trauma, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Fatigue, biological
(chronic fatigue syndrome, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Pain
(chronic, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Nervous system
(degeneration, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Mental disorder
(depression, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Gastrointestinal motility
(disorder, dysmotility, dysmotility, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Sexual behavior
(disorder, priapism, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Drug delivery systems
(emulsions; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT **Fertility**
(enhancement, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Heart, disease
Kidney, disease
(failure, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Stomach, disease
(gastritis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Kidney, disease
(glomerulonephritis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Transplant and Transplantation
(graft-vs.-host reaction, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Neoplasm
(hematol., nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Dialysis
(hemodialysis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Shock (circulatory collapse)
(hemorrhagic, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Appetite
(hyperphagia, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Intestine, disease
(ileitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Intestine
(ileum, disease, ileitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Liver, disease

Liver, disease
(inflammation, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Intestine, disease
(inflammatory, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(inhalants; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(injections, i.v.; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(injections, s.c.; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Head
Lung, disease
Reperfusion
(injury, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Brain, disease
(ischemia, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(liposomes; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(liqs., dispersions; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drugs
(lung injury induced by, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Meningitis
(lymphocytic choriomeningitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Headache
(migraine, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Myeloproliferative disorders
(myelofibrosis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Heart, disease
(myocarditis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Kidney, disease
(nephritis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT AIDS (disease)
Alzheimer's disease
Anaphylaxis
Anxiety
Arthritis
Asthma
Atherosclerosis
Autoimmune disease
Burn
Cachexia
Cardiopulmonary bypass
Cirrhosis
Cystic fibrosis
Dermatitis
Diabetes mellitus

Drug dependence
Eczema
Encephalomyelitis
Epilepsy
Heart, disease
Hepatitis
Infection
Inflammation
Ischemia
Liver, disease
Malaria
Meningitis
Multiple sclerosis
Neoplasm
Obesity
Parkinson's disease
Psoriasis
Schizophrenia
Transplant rejection
Ulcer
Urticaria
(nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Cytokines
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Interleukin 1
Interleukin 12
Interleukin 2
Interleukin 6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Interferons
Interleukins
Tumor necrosis factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Micelles
Scavengers
Spin trapping
(nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Lipopolysaccharides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT Antibiotics
Cardiovascular agents
(nitric oxide scavenger for in vivo redn. of nitric oxide level, and combination use)

IT Catecholamines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide scavenger for in vivo redn. of nitric oxide level, and

combination use)
IT Drug delivery systems
(oral; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Pancreas, disease
(pancreatitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(parenterals; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Peritoneum
(peritonitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Ovarian cycle
(premenstrual syndrome, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Transplant and Transplantation
(preservation, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(rectal; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Shock (circulatory collapse)
(septic, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Neoplasm
(solid, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(solids; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Drug delivery systems
(solns.; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Brain, disease
(stroke, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Lupus erythematosus
(systemic, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Shock (circulatory collapse)
(toxic shock syndrome, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Intestine, disease
(ulcerative colitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Eye, disease
(uveitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Blood vessel, disease
(vasculitis, nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., nitric oxide overprodn. assocd. with; nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT 160525-37-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide scavenger for in vivo redn. of nitric oxide level)
IT 151268-43-8

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT 74-79-3, L-Arginine, biological studies 125978-95-2, **Nitric oxide synthase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT 10102-43-9, Nitric oxide, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(nitric oxide scavenger for in vivo redn. of nitric oxide level)

IT 51-41-2, Noradrenaline 51-61-6, Dopamine, biological studies 34368-04-2, Dobutamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide scavenger for in vivo redn. of nitric oxide level, and combination use)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aisaka; Biochem Biophys Res Commun 1989, V160, P881 CAPLUS
(2) Aisaka; Biomed & Biophys Res Commun 1989, V163, P710 CAPLUS
(3) Akaike; Biochem & Biophys Res Commun 1994, V202, P923
(4) Alving; Eur Respir J 1993, V6, P1368 MEDLINE
(5) Anon; GB 901094 1962
(6) Anon; WO 95/30415 1995 CAPLUS
(7) Balter, M; Science 1995, V268, P205 CAPLUS
(8) Barnes; Immunology Today 1995, V16, P128 CAPLUS
(9) Bartholomew, B; Food Chem Toxic 1984, V22, P541 CAPLUS
(10) Bonsen; US 4265874 1981 CAPLUS
(11) Boughton-Smith; Lancet 1993, V342, P338 MEDLINE
(12) Bukrinsky; J Exp Med 1995, V181, P735 CAPLUS
(13) Cattell; Transplantation 1994, V58, P1399 CAPLUS
(14) Claria; Hepatology 1992, V15, P343 CAPLUS
(15) Corbett; Proc Natl Acad Sci 1993, V90, P1731 CAPLUS
(16) Devlin; Transplantation 1994, V58, P592 CAPLUS
(17) Dorheim; Biochem & Biophys Res Commun 1994, V205, P659 CAPLUS
(18) Eizirik; J Clin Invest 1994, V93, P1968 CAPLUS
(19) Hambrecht; J Leuk Biol 1992, V52, P390
(20) Kimble; US 4554108 1985 CAPLUS
(21) Kimble; US 4595538 1986 CAPLUS
(22) Lai; US 5358703 1994 CAPLUS
(23) Lommel; US 1863572 1932 CAPLUS
(24) Medford; US 5380747 1995 CAPLUS
(25) Sunderman; US 2876159 1959 CAPLUS
(26) Theeuwes; US 4160452 1979 CAPLUS
(27) Theeuwes; US 4256108 1981
(28) Wight; US 4166866 1979 CAPLUS

L17 ANSWER 13 OF 18 CAPLUS

AN 1998:755828 CAPLUS

DN 130:151457

TI Impaired ovulation in mice with targeted deletion of the neuronal isoform of **nitric oxide synthase**

AU Klein, Sabra L.; Carnovale, David; Burnett, Arthur L.; Wallach, Edward E.; Zacur, Howard A.; Crone, Julie K.; Dawson, Valina L.; Nelson, Randy J.; Dawson, Ted M.

CS Behavioral Neuroendocrinology Group, Department of Psychology, Johns Hopkins University, Baltimore, MD, USA

SO Molecular Medicine (New York) (1998), 4(10), 658-664
CODEN: MOMEF3; ISSN: 1076-1551
PB Springer-Verlag New York Inc.
DT Journal
LA English
CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 14
AB Background: Nitric oxide (NO) plays an important role in numerous reproductive processes. To date, most studies have assessed the role of NO by using nonspecific pharmacol. inhibitors of the precursor to NO, **nitric oxide synthase** (NOS). These pharmacol. NOS inhibitors suppress all isoforms of NOS; thus, the precise contribution of each isoform to female reproductive physiol. is unknown. The purpose of this study was to det. the specific role of neuronal NOS (nNOS) in the regulation of ovulation in female mice lacking the gene that encodes for nNOS (nNOS-/-). Materials and Methods: Ovulation was assessed in wild-type (WT) and nNOS-/- female mice by examg. the no. of ovarian rupture sites and no. of oocytes recovered from the oviducts following mating or exposure to exogenous gonadotropins (i.e., 5 IU pregnant mares serum gonadotropin [PMSG] and 5 IU human chorionic gonadotropin [hCG]). Ovulatory efficiency was detd. as the no. of ovulated oocytes per no. of ovarian rupture sites. To examine whether ovulatory deficits in nNOS-/- mice were due to alterations in central mechanisms, plasma LH concns. were assessed in WT and nNOS-/- mice that were challenged with 25 ng of gonadotropin-releasing hormone (GnRH). To det. whether ovulatory deficits in nNOS-/- mice were due to local ovulation processes, nerves innervating the reproductive tract of WT and nNOS-/- females were examd. for the presence of nNOS protein. Results: There were substantial **fertility** deficits in nNOS-/- female mice; the nNOS-/- mice had fewer oocytes in their oviducts following spontaneous and gonadotropin-stimulated ovulation. Pituitary responsiveness to exogenous GnRH challenge was intact in nNOS-/- mice. Dense nNOS protein staining was obsd. in nerves innervating the reproductive tracts of WT mice. Conclusions: The reproductive deficits in nNOS-/- females are most likely due to alterations in the transfer of oocytes from the ovaries to the oviducts during ovulation. These results suggest that defects in neuronally derived NO prodn. may contribute to female infertility.
ST **nitric oxide synthase** ovulation infertility
IT Mutation
(deletion; impaired ovulation in mice with targeted deletion of neuronal isoform of **nitric oxide synthase**)
IT **Fertility**
Fertility
(female, disorder; impaired ovulation in mice with targeted deletion of neuronal isoform of **nitric oxide synthase**)
IT Ovulation
(impaired ovulation in mice with targeted deletion of neuronal isoform of **nitric oxide synthase**)
IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(impaired ovulation in mice with targeted deletion of neuronal isoform of **nitric oxide synthase**)
IT 125978-95-2, **Nitric oxide synthase**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(neuronal isoform; impaired ovulation in mice with targeted deletion of neuronal isoform of **nitric oxide synthase**)
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Ben-Shlomo, I; Biol Reprod 1994, V51, P310 CAPLUS
(2) Bonello, N; Biol Reprod 1996, V54, P436 CAPLUS
(3) Bredt, D; Annu Rev Biochem 1994, V63, P175 CAPLUS
(4) Burnett, A; Mol Med 1996, V2, P288 CAPLUS
(5) Cavender, J; Biol Reprod 1988, V39, P989 MEDLINE
(6) Collins, T; Neurobiol Aging 1981, V2, P125 CAPLUS
(7) Demas, G; Mol Med 1997, V3, P610 CAPLUS
(8) Epsey, L; Biol Reprod 1980, V22, P73
(9) Grozdanovic, Z; Cell Tissue Res 1994, V275, P355 MEDLINE
(10) Hays, W; Statistics Fort Worth:Harcourt Brace 1994
(11) Herdegen, T; J Neurosci 1993, V13, P4130 CAPLUS
(12) Hesla, J; Fertil Steril 1997, V67, P48
(13) Huang, P; Cell 1993, V75, P1273 CAPLUS
(14) Hurwitz, A; Endocrinology 1992, V131, P1643 CAPLUS
(15) Jarrett, W; Neurosci Lett 1994, V177, P47 CAPLUS
(16) Lowenstein, C; Methods Enzymol 1994, V233, P264 CAPLUS
(17) Macmicking, J; Cell 1995, V81, P641 CAPLUS
(18) Moretto, M; Endocrinology 1993, V133, P2399 CAPLUS
(19) Nelson, R; Frontiers Neuroendocrinol 1997, V18, P463 CAPLUS
(20) Nelson, R; Nature 1995, V378, P383 CAPLUS
(21) Powers, R; Am J Physiol 1995, V269, PE290 CAPLUS
(22) Rafferty, K; Methods in Experimental Embryology of the Mouse 1970
(23) Redina, O; J Reprod Fertil 1994, V102, P263 MEDLINE
(24) Rehman, J; Am J Physiol 1997, V272, PH1960 CAPLUS
(25) Rettori, V; Proc Natl Acad Sci U S A 1993, V90, P10130 CAPLUS
(26) Roskams, A; Neuron 1994, V13, P289 CAPLUS
(27) Shukovski, L; Endocrinology 1994, V135, P2287 CAPLUS
(28) Takehara, Y; Endocrinology 1994, V134, P788
(29) Wilson, R; Nature 1997, V386, P338 CAPLUS

L17 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:370682 CAPLUS
DN 129:118187
TI Chronic blockade of **nitric oxide-synthase** and endothelin receptors during pregnancy in the rat: effect on pregnancy outcome
AU Wight, Edward; Kung, Christoph F.; Moreau, Pierre; Takase, Hiroyuki; Luscher, Thomas F.
CS Department of Obstetrics and Gynecology, University Hospital Zurich, Zurich, CH-8091, Switz.
SO Journal of the Society for Gynecologic Investigation (1998), 5(3), 132-139
CODEN: JSGIED; ISSN: 1071-5576
PB Elsevier Science Inc.
DT Journal
LA English
CC 2-10 (Mammalian Hormones)
AB To investigate the effects of endothelin-1 (ET-1) receptor antagonism and/or chronic blockade of nitric oxide (NO) prodn. on pregnancy outcome in the rat. Pregnant or nonpregnant Wistar rats were either treated orally for up to 18 days with the NO-synthase inhibitor N.omega.-nitro-L-arginine Me ester (L-NAME), the ETA-/ETB-receptor antagonist bosentan or both, or received no treatment (controls). Blood pressure, body wt., and drug intake were measured at regular intervals. Pregnancy outcome and proteinuria were also detd. Anal. of variance and paired Student t test were used for statistical anal. Chronic L-NAME treatment increased systolic blood pressure by 69 and 64 mmHg in pregnant and virgin rats resp. Bosentan-blunted, L-NAME-induced hypertension at the beginning, but not at the end of the treatment period in all rats examd. N.omega.-nitro-L-arginine Me ester-treatment in pregnancy reduced the no. of living fetuses at term and caused proteinuria. Bosentan tended to reverse the effects of L-NAME on fetus no. and proteinuria, but both effects failed to reach statistical significance. The effects of chronic

NO-synthase-blockade on blood pressure in gravid rats can be reversed only temporarily by ETA-/ETB-antagonism, suggesting an involvement of endothelin-1 in the early phase of the L-NAME-induced, preeclampsia-like syndrome during pregnancy, although at later stages other mechanisms may come into play.

ST pregnancy nitric oxide endothelin receptor

IT **Fertility**
(female; **nitric oxide-synthase** and endothelin receptor chronic blockade effect on pregnancy outcome in rats)

IT Pregnancy
(**nitric oxide-synthase** and endothelin receptor chronic blockade effect on pregnancy outcome in rats)

IT Endothelin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**nitric oxide-synthase** and endothelin receptor chronic blockade effect on pregnancy outcome in rats)

IT 10102-43-9, Nitric oxide, biological studies 123626-67-5, Endothelin-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**nitric oxide-synthase** and endothelin receptor chronic blockade effect on pregnancy outcome in rats)

IT 116243-73-3, Endothelin 125978-95-2, **Nitric oxide synthase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**nitric oxide-synthase** and endothelin receptor chronic blockade effect on pregnancy outcome in rats)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Baylis, C; Clin Exp Hypertens Pregnancy 1992, VB11, P117 CAPLUS
(2) Boulanger, C; Circ Res 1992, V70, P1191 CAPLUS
(3) Boulanger, C; J Clin Invest 1990, V85, P587 CAPLUS
(4) Bunag, R; Hypertension 1982, V4, P898 MEDLINE
(5) Clozel, M; J Pharmacol Exp Ther 1994, V270, P228 CAPLUS
(6) Diket, A; Am J Obstet Gynecol 1994, V171, P1243 CAPLUS
(7) Furchgott, R; Ann Rev Pharmacol Toxicol 1984, V24, P175 CAPLUS
(8) Garg, U; J Clin Invest 1989, V83, P1774 CAPLUS
(9) Goerre, S; Circulation 1995, V91, P359 MEDLINE
(10) Grieff, M; Transplantation 1993, V56, P880 MEDLINE
(11) Helmbrecht, G; Am J Obstet Gynecol 1996, V175, P800 CAPLUS
(12) Jaffer, F; Kidney Int 1990, V38, P1193 CAPLUS
(13) Joannides, R; Circulation 1995, V91, P1314 CAPLUS
(14) Kamoi, K; N Engl J Med 1990, V323, P1486 MEDLINE
(15) Konishi, M; Hypertension 1983, V5, P881 CAPLUS
(16) Kurihara, Y; Nature 1994, V368, P703 CAPLUS
(17) Li, J; Hypertension 1994, V24, P183 CAPLUS
(18) Luscher, T; Hypertension 1986, V8(Suppl 2), P55
(19) Luscher, T; J Cardiovasc Pharmacol 1994, V24(Suppl 3), PS16
(20) Luscher, T; The endothelium:Modulator of cardiovascular function 1990
(21) Macgillivray, I; Clin Sci 1969, V37, P395 MEDLINE
(22) Magness, R; Semin Perinatol 1991, V15, P68 MEDLINE
(23) Masaki, T; Semin Perinatol 1991, V15, P27 MEDLINE
(24) Molnar, M; Am J Obstet Gynecol 1994, V170, P1458 CAPLUS
(25) Nava, E; Circulation 1995, V91, P2310 CAPLUS
(26) Palmer, S; Obstet Gynecol 1992, V80, P1000 MEDLINE
(27) Peeters, L; Am J Obstet Gynecol 1980, V138, P1177 MEDLINE
(28) Rapoport, R; Circ Res 1983, V52, P352 CAPLUS
(29) Rees, D; Br J Pharmacol 1990, V101, P746 CAPLUS
(30) Richard, V; Circulation 1995, V91, P771 CAPLUS
(31) Schiff, E; Am J Obstet Gynecol 1992, V166, P624 MEDLINE
(32) Stewart, D; Am J Physiol 1990, V259, PH1928 CAPLUS

(33) Tabuchi, Y; Biochemical Biophys Res Commun 1989, V159, P1304 CAPLUS
(34) Taddei, S; Hypertension 1993, V21, P929 MEDLINE
(35) Takase, H; Hypertension 1996, V27, P25 CAPLUS
(36) Tanner, F; Circulation 1991, V83, P2012 CAPLUS
(37) Weiner, C; Am J Obstet Gynecol 1992, V166, P1171 CAPLUS
(38) Weiner, C; Proc Natl Acad Sci U S A 1994, V91, P5212 CAPLUS
(39) Yallampalli, C; Am J Obstet Gynecol 1993, V169, P1316 CAPLUS
(40) Yanagisawa, M; Nature 1988, V332, P411 CAPLUS
(41) Yokokawa, K; Hypertension 1991, V18, P304 CAPLUS
(42) Yoshimoto, S; Stroke 1991, V22, P378 MEDLINE

L17 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1998:180841 CAPLUS
DN 128:239488
TI Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
IN Lai, Ching-San
PA Medinox, Inc., USA; Lai, Ching-San
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C333-14
CC 1-12 (Pharmacology)
Section cross-reference(s): 8
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811066	A1	19980319	WO 1997-US15324	19970828
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741725	A1	19980402	AU 1997-41725	19970828
	AU 746790	B2	20020502		
	EP 927159	A1	19990707	EP 1997-939694	19970828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1230178	A	19990929	CN 1997-197797	19970828
	JP 2002511837	T2	20020416	JP 1998-513688	19970828
	KR 2000035992	A	20000626	KR 1999-7001945	19990309
PRAI	US 1996-25867P	P	19960910		
	US 1997-899087	A2	19970723		
	US 1996-25867	A	19960910		
	WO 1997-US15324	W	19970828		

OS MARPAT 128:239488
AB A new class of drugs is provided for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Dithiocarbamates are linked to the surface of a macromol. (e.g. albumin), either by using crosslinking reagents or by non-specific binding, to produce polydithiocarbamate-macromol.-contg. compns. Combination therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible **nitric oxide synthase**, as well as reducing nitric oxide levels produced as a result of NO synthase expression. Magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct vol. in ischemic stroke or heart attack situations. Such methods

employ iron-contg. complexes of a compn. comprising a dithiocarbamate and a macromol. as contrast agents. Prepn. of a reaction product of bovine serum albumin with N-methyl-D-glucamine dithiocarbamate is described.

ST dithiocarbamate macromol therapeutic diagnostic; albumin dithiocarbamate therapeutic diagnostic; MRI contrast dithiocarbamate macromol iron complex; cerebral stroke ischemia reperfusion dithiocarbamate macromol; **nitric oxide synthase** dithiocarbamate macromol

IT AIDS (disease)
AIDS (disease)
(AIDS dementia complex; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Mental disorder
Mental disorder
(AIDS dementia; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Nervous system
(Huntington's chorea; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Imaging agents
Imaging agents
(NMR contrast; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Respiratory distress syndrome
(adult; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Skin, disease
(aging, disorder, photoaging, and photodamage; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Transplant rejection
(allotransplant; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Nervous system
(amyotrophic lateral sclerosis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Nervous system
Nervous system
(central, trauma; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Fatigue, biological
(chronic fatigue syndrome; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Nervous system
(degeneration; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Gastrointestinal motility
(disorder, dysmotility, dysmotility; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT **Fertility**
(enhancement; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Heart, disease
Kidney, disease
(failure; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Drugs
(gastrointestinal; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Kidney, disease
(glomerulonephritis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Transplant and Transplantation
(graft-vs.-host reaction; polydithiocarbamate-contg. macromols. for

therapeutic and diagnostic applications)
IT Antitumor agents
Antitumor agents
(hematol.; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Dialysis
(hemodialysis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Shock (circulatory collapse)
(hemorrhagic; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Appetite
(hyperphagia; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Intestine, disease
(ileitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Intestine
(ileum, disease, ileitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Intestine, disease
(inflammatory; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Head
Lung, disease
Reperfusion
(injury; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Brain, disease
(ischemia, focal; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Brain, disease
(ischemia; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Infection
(leading to overprodn. of inflammatory cytokines; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Drugs
(lung injury from; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Meningitis
(lymphocytic choriomeningitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Myeloproliferative disorders
(myelofibrosis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Heart, disease
(myocarditis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Cytoprotective agents
(neuroprotectants; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Scavengers
(nitric oxide; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Pancreas, disease
(pancreatitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Peritoneum
(peritonitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)
IT Skin, disease

(photoaging, and photodamage; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Analgesics
Anaphylaxis
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Anticonvulsants
Antidepressants
Antidiabetic agents
Antimalarials
Antimigraine agents
Antiobesity agents
Antiparkinsonian agents
Antitumor agents
Antiulcer agents
Anxiolytics
Autoimmune disease
Burn
Cachexia
Cardiovascular agents
Cirrhosis
Cystic fibrosis
Dermatitis
Drug delivery systems
Drug dependence
Eczema
Encephalomyelitis
Eye, disease
Hepatitis
Liver, disease
Meningitis
Multiple sclerosis
Nervous system agents
Organ preservation
Psoriasis
Schizophrenia
Shock (circulatory collapse)
Transplant rejection
Urticaria
(polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Ovarian cycle
(premenstrual syndrome; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Penis
(priapism; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Hemocyanins
Nucleic acids
Ovalbumin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction products with dithiocarbamates; polydithiocarbamate-contg.

macromols. for therapeutic and diagnostic applications)

IT Albumins, biological studies
Polysaccharides, biological studies
Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction products, with dithiocarbamates; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Albumins, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Shock (circulatory collapse)
(septic; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Antitumor agents
(solid tumor; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Brain, disease
(stroke; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Lupus erythematosus
(systemic; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Shock (circulatory collapse)
(toxic shock syndrome; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Bacteria (Eubacteria)
(translocation; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Shock (circulatory collapse)
(traumatic; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT Blood vessel, disease
(vasculitis; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT 125978-95-2, **Nitric oxide synthase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inducible; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT 7439-89-6, Iron, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(overload; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT 594-07-0D, Dithiocarbamic acid, dithiocarbamate-macromol. products
1398-61-4D, Chitin, dithiocarbamate reaction products 7439-89-6D, Iron, complexes with dithiocarbamate-macromol. products, biological studies
9000-07-1D, Carrageenan, dithiocarbamate reaction products 9000-30-0D, Guar gum, dithiocarbamate reaction products 9000-40-2D, Locust bean gum, dithiocarbamate reaction products 9000-69-5D, Pectin, dithiocarbamate reaction products 9004-34-6D, Cellulose, dithiocarbamate reaction products, biological studies 9004-54-0D, Dextran, dithiocarbamate reaction products, biological studies 9004-61-9D, Hyaluronic acid, dithiocarbamate reaction products 9005-25-8D, Starch, dithiocarbamate reaction products, biological studies 9005-32-7D, Alginic acid, dithiocarbamate reaction products 9005-49-6D, Heparin, dithiocarbamate reaction products, biological studies 9005-79-2D, Glycogen, dithiocarbamate reaction products, biological studies 9005-80-5D, Inulin, dithiocarbamate reaction products 9012-36-6D, Agarose, dithiocarbamate reaction products 9012-76-4D, Chitosan, dithiocarbamate

reaction products 9013-95-0D, Levan, dithiocarbamate reaction products 11138-66-2D, Xanthan gum, dithiocarbamate reaction products 29894-36-8D, Polymannuronic acid, dithiocarbamate reaction products 39464-87-4D, Scleroglucan, dithiocarbamate reaction products 71010-52-1D, Gellan gum, dithiocarbamate reaction products 94161-07-6D, albumin reaction products
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT 94161-07-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

IT 10102-43-9, Nitric oxide, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(scavenger; polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Demuth; US 5387748 A 1995 CAPLUS

L17 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS

AN 1997:745947 CAPLUS

DN 128:19047

TI Improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor

IN Chwalsz, Krzysztof; Garfield, Robert E.

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565
ICS A61K031-57; A61K031-22; A61K031-195; A61K031-34; A61K031-44

CC 2-3 (Mammalian Hormones)
Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741866	A1	19971113	WO 1997-EP2371	19970507
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6040340	A	20000321	US 1996-646518	19960507
	AU 9728947	A1	19971126	AU 1997-28947	19970507
	EP 906105	A1	19990407	EP 1997-923032	19970507
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1218402	A	19990602	CN 1997-194452	19970507
	BR 9708980	A	19990803	BR 1997-8980	19970507
	JP 2000510462	T2	20000815	JP 1997-539553	19970507
	NO 9805204	A	19990106	NO 1998-5204	19981106
	KR 2000010833	A	20000225	KR 1998-708974	19981106
PRAI	US 1996-646518	A	19960507		
	WO 1997-EP2371	W	19970507		

AB A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amt. of: (a) a **nitric oxide synthase** substrate, a nitric oxide donor, or both, optionally in combination with, (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for **fertility** control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk of becoming pregnant an effective amt. of **nitric oxide synthase** inhibitor in combination with an antiprogestin. Pharmaceutical compns. are also provided.

ST implantation in vitro fertilization nitric oxide; contraceptive **nitric oxide synthase** inhibitor antiprogestin

IT Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiprogestins; **fertility** control using a **nitric oxide synthase** inhibitor in combination with an antiprogestin)

IT **Fertility**
(female, disorder; improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT **Fertility**
(female, female **fertility** disorders; improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT Contraceptives
(**fertility** control using a **nitric oxide synthase** inhibitor in combination with an antiprogestin)

IT Embryo, animal
(improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT Estrogens
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor and optionally a progestin and estrogen)

IT Fertilization
(in vitro; improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT Pregnancy
(rate; improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT Abortion
(spontaneous; prevention of early pregnancy loss by administering a nitric oxide substrate and/or donor)

IT 79-17-4, Aminoguanidine 504-29-0, 2-Aminopyridine 1121-58-0, 4-Methylaminopyridine 5407-87-4, 4,6-Dimethyl-2-aminopyridine 17035-90-4 36889-13-1 52450-18-7, AMT 53774-63-3 80471-63-2, Epostane 84371-65-3, Mifepristone 118968-41-5, ORG 31710 126784-99-4, CDB2914 155768-17-5, ORG 33628 198907-45-8, ZK 137316 199396-76-4, J 867
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**fertility** control using a **nitric oxide synthase** inhibitor in combination with an antiprogestin)

IT 55-63-0, Nitroglycerin 74-79-3, L-Arginine, biological studies

87-33-2, Isosorbide dinitrate 10102-43-9D, Nitric oxide, substrates and donors 14402-89-2, Sodium nitroprusside 16051-77-7, Isosorbide mononitrate 33876-97-0, SIN-1 125978-95-2D, **Nitric oxide synthase**, substrates and inhibitors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor)

IT 50-28-2, Estradiol, biological studies 57-83-0, Progesterone, biological studies 630-56-8, Hydroxyprogesterone caproate 979-32-8, Estradiol valerate 96346-61-1, Onapristone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor and optionally a progestin and estrogen)

L17 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1996:324262 CAPLUS
DN 125:54130
TI The immunohistochemical localization of **nitric oxide synthase** (NOS) in the human male reproductive tract and in spermatozoa, suggests a possible role for nitric oxide in spermatogenesis and sperm maturation and an association with subfertility.
AU Zini, Armand; O'Bryan, Moira K.; Magid, Margaret; Schlegel, Peter N.
CS Department Urology, James Buchanan Brady Foundation, New York, NY, 10021, USA
SO Portland Press Proceedings (1996), 10(Biology of Nitric Oxide Part 5), 19
CODEN: POPPEF; ISSN: 0966-4068
PB Portland Press
DT Journal
LA English
CC 13-1 (Mammalian Biochemistry)
Section cross-reference(s): 14
AB **Nitric oxide synthase** (NOS) was present in the human male reproductive tract and in spermatozoa. The NOS was distributed throughout the cytoplasm of Leydig cells and Sertoli cells in normal and subjects with subfertility. The NOS in the epididymis and vas deferens was almost exclusively confined to the epithelium. Thus, the NOS may play an important role in the function of the human male reproductive system.
ST NO synthase male reproductive tract sperm; subfertility NO synthase male reproductive tract
IT Cytoplasm
Epididymis
Vas deferens
(localization and role of **nitric oxide synthase** in human male reproductive tract and in spermatozoa)
IT Sperm
(localization and role of **nitric oxide synthase** in normal and subfertile human male reproductive tract and in spermatozoa)
IT Testis
(Leydig cell, localization and role of **nitric oxide synthase** in human male reproductive tract and in spermatozoa)
IT Testis
(Sertoli cell, localization and role of **nitric oxide synthase** in human male reproductive tract and in spermatozoa)
IT **Fertility**
(disorder, subfertility, localization and role of **nitric**

oxide synthase in human male reproductive tract and in spermatozoa)

IT Reproductive tract
(male, localization and role of **nitric oxide synthase** in normal and subfertile human male reproductive tract and in spermatozoa)

IT 125978-95-2, **Nitric oxide synthase**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(localization and role of **nitric oxide synthase** in normal and subfertile human male reproductive tract and in spermatozoa)

L17 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1995:688648 CAPLUS
DN 123:80417
TI **Nitric oxide synthase** in the rat fallopian tube is regulated during the estrous cycle
AU Bryant, C. E.; Tomlinson, A.; Mitchell, J. A.; Thiemermann, C.; Willoughby, D. A.
CS Dep. Exp. Pathol., Med. Coll. St. Bartholomew's Hosp., London, EC1M 6BQ, UK
SO Journal of Endocrinology (1995), 146(1), 149-57
CODEN: JOENAK; ISSN: 0022-0795
PB Journal of Endocrinology
DT Journal
LA English
CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 2, 7
AB Nitric oxide produced from L-arginine by **nitric oxide synthase** (NOS) acts in a variety of biol. processes via the stimulation of guanylyl cyclase and subsequent elevation of cGMP. Constitutive, calcium-dependent isoforms of NOS are found in endothelial cells (eNOS) and neurons (nNOS), while macrophages express an inducible, calcium-independent isoform (iNOS) in response to the action of certain cytokines or bacterial endotoxin. While the regulation of NOS by exogenous glucocorticoids and steroid hormones as well documented, the effects of endogenous steroid hormones on NOS activity, such as those released during the estrous cycle, is unknown. Here the authors demonstrate, using specific antibodies for eNOS, nNOS and iNOS, the presence of NOS in the epithelium of rat fallopian tubes at proestrus, late proestrus, estrus, metestrus and diestrus. Western blot anal. of rat fallopian tube homogenates revealed a protein band at approx. 125 kDa, which was recognized by antibodies to different isoforms of NOS, but no bands at the expected mol. wts. (eNOS, 140 kDa; nNOS, 160 kDa; iNOS, 135 kDa). NOS activity in fallopian tubes was measured by the conversion of L-[3H]arginine to L-[3H]citrulline. Both calcium-dependent and -independent NOS activities were present. However, in late proestrus when circulating estrogens are low, NOS activity was reduced in comparison to all other stages of the estrous cycle. Thus the authors show that NOS is present in the epithelial lining of the fallopian tube and is recognized at a previously undescribed mol. wt. The changes in NOS activity in these cells during the estrous cycle may modulate tube motility and contribute to successful **fertility.**
ST **nitric oxide synthase** oviduct; ovarian cycle **nitric oxide synthase**
IT Ovarian cycle
(**nitric oxide synthase** isoforms in rat fallopian tube in relation to estrous cycle)
IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(**nitric oxide synthase** isoforms in rat
fallopian tube in relation to estrous cycle)
IT Oviduct
(epithelium, **nitric oxide synthase**
isoforms in rat fallopian tube in relation to estrous cycle)
IT 125978-95-2, **Nitric oxide synthase**
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(**nitric oxide synthase** isoforms in rat
fallopian tube in relation to estrous cycle)
IT 10102-43-9, Nitric oxide, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**nitric oxide synthase** isoforms in rat
fallopian tube in relation to estrous cycle)

=> e implantation
E1 1 IMPLANTATIOH/BI
E2 1 IMPLANTATIOM/BI
E3 78734 --> IMPLANTATION/BI
E4 27 IMPLANTATIONAL/BI
E5 1 IMPLANTATIONAND/BI
E6 1 IMPLANTATIONAT/BI
E7 1 IMPLANTATIONG/BI
E8 2 IMPLANTATIONIN/BI
E9 2 IMPLANTATIONM/BI
E10 2 IMPLANTATIONN/BI
E11 1 IMPLANTATIONNALLY/BI
E12 1 IMPLANTATIONON/BI

=> s e3
L18 78734 IMPLANTATION/BI

=> s l18 and l12
L19 99 L18 AND L12

=> s l19 and l13
L20 5 L19 AND L13

=> d l20 1-5

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2002:869589 CAPLUS
DN 137:346927
TI **Implantation** rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
IN Chwalisz, Krzysztof; Garfield, Robert E.
PA Germany
SO U.S. Pat. Appl. Publ., 15 pp., Division of U.S. Ser. No. 162,446.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002169205	A1	20021114	US 2002-43232	20020114

PRAI US 1998-162446 A3 19980929

L20 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1999:203927 CAPLUS
DN 131:39874
TI Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat
AU Chwalisz, Kristof; Winterhager, Elke; Thienel, Thomas; Garfield, Robert E.
CS Research Laboratories of Schering AG, Berlin, 13342, Germany
SO Human Reproduction (1999), 14(2), 542-552
CODEN: HUREEE; ISSN: 0268-1161
PB Oxford University Press
DT Journal
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1998:309186 CAPLUS
DN 129:79672
TI Chronic nitric oxide synthesis inhibition does not prevent pregnancy vasodilation in the rat
AU Ahokas, Robert A., Ph. D.; Lubarsky, Suzanne L., M. D.; Park, Gun-Chae, M. D.; Friedman, Steven A., M. D.; Sibai, Baha M., M. D.
CS Department of Obstetrics and Gynecology, University of Tennessee, Memphis, TN, USA
SO Hypertension in Pregnancy (1998), 17(1), 55-68
CODEN: HYPPEV; ISSN: 1064-1955
PB Marcel Dekker, Inc.
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1997:572956 CAPLUS
DN 127:242956
TI Differential effect of L-NAME and S-methyl-isothiourea on leukocyte emigration in carrageenin-soaked sponge implants in rat
AU Iuvone, Teresa; Van Osselaer, Nancy; D'acquisto, Fulvio; Carnuccio, Rosa; Herman, Arnold G.
CS Division of Pharmacology, Faculty of Medicine, University of Antwerpen (UIA), Antwerpen-Wilrijk, B-2610, Belg.
SO British Journal of Pharmacology (1997), 121(8), 1637-1644
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton
DT Journal
LA English

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1995:259445 CAPLUS
DN 122:71778
TI Inhibitors of **nitric oxide synthase** as potential treatments for opioid withdrawal
AU London, E. D.; Vaupel, D. B.; Kimes, A. S.
CS Neuroimaging and Drug Action Section, Natl. Inst. Drug Abuse, Baltimore, MD, USA
SO Regulatory Peptides (1994), 54(1), 165-6
CODEN: REPPDY; ISSN: 0167-0115
PB Elsevier
DT Journal
LA English

=> d l20 3-5 all

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1998:309186 CAPLUS
DN 129:79672
TI Chronic nitric oxide synthesis inhibition does not prevent pregnancy vasodilation in the rat
AU Ahokas, Robert A., Ph. D.; Lubarsky, Suzanne L., M. D.; Park, Gun-Chae, M. D.; Friedman, Steven A., M. D.; Sibai, Baha M., M. D.
CS Department of Obstetrics and Gynecology, University of Tennessee, Memphis, TN, USA
SO Hypertension in Pregnancy (1998), 17(1), 55-68
CODEN: HYPPEV; ISSN: 1064-1955
PB Marcel Dekker, Inc.
DT Journal
LA English
CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 1
AB The objective is to det. if blockade of endothelium-derived nitric oxide synthesis from the day after embryo **implantation** to the day before parturition prevents maternal systemic vasodilation in the rat. Timed-pregnant and age-matched nonpregnant Wistar-Kyoto rats were administered the nonselective **nitric oxide synthase** inhibitor N.omega.-nitro-L-arginine Me ester (15 mg/rat/day, s.c.) or saline vehicle (untreated) for 14 days using osmotic minipumps. On the last day of treatment (day 20 of gestation in the pregnant rats), plasma total nitrate/nitrite concn., mean arterial blood pressure, and heart rate were measured. Cardiac output and organ blood flows were then measured using radioactive-labeled microspheres for the calcn. of total systemic and organ/tissue vascular conductances, resp. Chronic blockade of nitric oxide synthesis decreased plasma nitrate/nitrite concn. >90% and induced hypertension with decreased cardiac output and organ blood flows in both nonpregnant and pregnant rats. Cardiac output and total vascular conductance were significantly increased in the pregnant compared to nonpregnant, untreated normotensive rats and in nitric-oxide-blocked hypertensive rats. Vascular conductance of the skin, skeletal muscle/skeleton, gastrointestinal tract, heart, and uterus were significantly greater in pregnant than in nonpregnant rats of both treatment groups. Conclusions: Maternal systemic and uterine vasodilation during pregnancy is complex and is caused by some mechanism(s) other than increased basal endothelium-derived nitric oxide prodn. or by a compensatory increase in some other vasodilatory system during nitric oxide synthesis blockade.
ST nitric oxide inhibition pregnancy vasodilation relationship
IT Blood pressure
Circulation
Pregnancy
Vasodilation
(pregnancy vasodilation independent of chronic nitric oxide synthesis inhibition)
IT **50903-99-6**, N.omega.-Nitro-L-arginine methyl ester
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pregnancy vasodilation independent of chronic nitric oxide synthesis inhibition)
IT 125978-95-2, **Nitric oxide synthase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pregnancy vasodilation independent of chronic nitric oxide synthesis inhibition)

IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pregnancy vasodilation independent of chronic nitric oxide synthesis inhibition)

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Ahokas, R; Am J Obstet Gynecol 1990, V162, P841 MEDLINE
(2) Ahokas, R; Am J Obstet Gynecol 1991, V165, P801 CAPLUS
(3) Aisaka, K; Biochem Biophys Res Commun 1989, V160, P881 CAPLUS
(4) Baylis, C; Hypertens Pregn 1994, V13, P342
(5) Buhimschi, I; Human Reprod 1995, V10, P2723 CAPLUS
(6) Conrad, K; Am J Physiol 1989, V257, PR847 CAPLUS
(7) Conrad, K; Am J Physiol 1994, V266, PR1267 CAPLUS
(8) Conrad, K; FASEB J 1993, V7, P566 CAPLUS
(9) Danielson, L; Circ Res 1996, V79, P1161 CAPLUS
(10) Dong, Y; J Reprod Fertil 1996, V107, P249 CAPLUS
(11) Garland, H; J Endocrinol 1987, V113, P435 CAPLUS
(12) Gilson, J; Am J Physiol 1992, V263, PH1911
(13) Goetz, R; Biochem Biophys Res Commun 1994, V205, P905 CAPLUS
(14) Green, L; Anal Biochem 1982, V126, P131 CAPLUS
(15) Helmbrecht, G; Am J Obstet Gynecol 1996, V175, P800 CAPLUS
(16) Ignarro, L; Annu Rev Pharmacol Toxicol 1985, V25, P171 MEDLINE
(17) Liao, P; Human Reprod 1996, V11, P2777
(18) Lubarsky, S; Am J Obstet Gynecol 1997, V176, P1069 CAPLUS
(19) Magness, R; Am J Physiol 1993, V265, PE690 CAPLUS
(20) Miller, A; Biol Reprod 1980, V22, P751 CAPLUS
(21) Molnar, M; Am J Obstet Gynecol 1992, V166, P1560 CAPLUS
(22) Molnar, M; Am J Obstet Gynecol 1994, V170, P1458 CAPLUS
(23) Moncada, S; Pharmacol Rev 1991, V43, P109 CAPLUS
(24) Morris, N; Br J Obstet Gynecol 1996, V103, P4 CAPLUS
(25) Nathan, L; Br J Pharmacol 1995, V114, P955 CAPLUS
(26) Ni, Y; Am J Obstet Gynecol 1997, V176, P856 CAPLUS
(27) Puri, C; Biol Reprod 1982, V27, P967 CAPLUS
(28) Rees, D; Proc Natl Acad Sci USA 1989, V86, P3375 CAPLUS
(29) Slangen, B; Am J Physiol 1996, V270, PH1779 CAPLUS
(30) Suto, T; Hypertens Pregn 1997, V16, P68
(31) Ueda, S; Am J Obstet Gynecol 1986, V155, P195 CAPLUS
(32) Umans, J; Am J Physiol 1990, V259, PF293 CAPLUS
(33) Waldman, S; Pharmacol Rev 1987, V39, P163 CAPLUS
(34) Weiner, C; Am J Obstet Gynecol 1989, V161, P1599 CAPLUS
(35) Weiner, C; Am J Obstet Gynecol 1994, V171, P838 CAPLUS
(36) Weiner, C; Proc Natl Acad Sci USA 1994, V91, P5212 CAPLUS
(37) Whittle, B; Br J Pharmacol 1989, V98, P646 CAPLUS
(38) Yallampalli, C; Am J Obstet Gynecol 1993, V169, P1316 CAPLUS

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1997:572956 CAPLUS
DN 127:242956
TI Differential effect of L-NAME and S-methyl-isothiourea on leukocyte emigration in carrageenin-soaked sponge implants in rat
AU Iuvone, Teresa; Van Osselaer, Nancy; D'acquisto, Fulvio; Carnuccio, Rosa; Herman, Arnold G.
CS Division of Pharmacology, Faculty of Medicine, University of Antwerpen (UIA), Antwerpen-Wilrijk, B-2610, Belg.
SO British Journal of Pharmacology (1997), 121(8), 1637-1644
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton
DT Journal
LA English
CC 1-7 (Pharmacology)
Section cross-reference(s): 14, 15
AB The role of nitric oxide (NO) in leukocyte (polymorphonuclear cells,

monocytes and lymphocytes) emigration was studied in a model of carrageenin-sponge implants in rats. The s.c. **implantation** of 1% (w/v) of .lambda.-carrageenin-soaked sponges elicited an inflammatory response that was characterized by a time-related increase in leukocyte infiltration in the sponges and increased levels of nitrite in the exudate. Total leukocyte infiltration and nitrite prodn. were maximal at 24 h and decreased after 48 and 96 h. The mononuclear cell influx was maximal at 48 h (21% of the total leukocytes). Therefore, this time point was used in the successive expts. Polymorphonuclear cell (PMN) and lymphocyte infiltration in the sponges significantly increased when rats were treated with the non-specific NO-synthase (NOS) inhibitor, NG-nitro-L-arginine methylester (L-NAME) (1 mg ml-1 in drinking water ad libitum). Monocyte emigration was not affected by L-NAME treatment. The nitrite levels in the exudate of L-NAME-treated rats were significantly reduced. The concomitant ingestion of L-arginine (30 mg ml-1) resulted in a reversion of the L-NAME effect, while D-arginine (30 mg ml-1) had no effect, indicating the involvement of the L-arginine: NO pathway. Administration of L-NAME resulted also in an increased release of tumor necrosis factor-.alpha. (TNF-.alpha.) and prostacyclin (measured as the stable metabolite, 6-keto-PGF1.alpha.). L-NAME had no effect on monocyte chemoattractant protein-1 (MCP-1) release in the exudate. Since L-NAME may have effects on the local blood flow, phenylephrine (0.034 mg ml-2 in drinking water) was used as it has an effect on the local blood flow similar to L-NAME. Phenylephrine had no effect on either leukocyte emigration, or on nitrite, TNF-.alpha., prostacyclin or MCP-1 accumulation in the exudate. In contrast, the more selective iNOS inhibitor S-methyl-isothiourea (SMT) (10 .mu.g ml-1 in drinking water) significantly reduced PMNs and lymphocyte influx in the sponge, having no effect on monocyte influx. Moreover, SMT decreased nitrite prodn. in the exudate to a comparable extent as L-NAME. Administration of SMT significantly reduced MCP-1 release in the exudate, without an effect on TNF-.alpha. or prostacyclin prodn. Moreover SMT did not produce any changes in local blood flow. The results show that a different outcome of the inflammatory process can be obtained depending on the types of NOS inhibitor used. Furthermore, by inhibiting leukocyte infiltration, the more specific iNOS inhibitors may be useful in the treatment of certain inflammatory reactions which are assocd. with an enhanced formation of NO due to the induction of iNOS.

ST leukocyte emigration inflammation NAME methylisothiourea; **nitric oxide synthase** inhibitor leukocyte emigration

IT Anti-inflammatory agents
Inflammation
Monocyte
Polymorphonuclear leukocyte
(differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT Monocyte chemoattractant protein-1
Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT Cell migration
(leukocyte; differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT Cell migration
(lymphocyte; differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge

implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT Leukocyte
Lymphocyte
(migration; differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT 2986-19-8, S-Methyl-isothiourea **50903-99-6**, NG-Nitro-L-arginine methylester,
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

IT 10102-43-9, Nitric oxide, biological studies 35121-78-9, Prostacyclin 58962-34-8 125978-95-2, **Nitric oxide synthase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(differential effect of L-NAME and methyl-isothiourea on leukocyte emigration in inflammation from carrageenin-soaked sponge implants in rat in relation to role of nitric oxide and inflammatory mediators)

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1995:259445 CAPLUS
DN 122:71778
TI Inhibitors of **nitric oxide synthase** as potential treatments for opioid withdrawal
AU London, E. D.; Vaupel, D. B.; Kimes, A. S.
CS Neuroimaging and Drug Action Section, Natl. Inst. Drug Abuse, Baltimore, MD, USA
SO Regulatory Peptides (1994), 54(1), 165-6
CODEN: REPPDY; ISSN: 0167-0115
PB Elsevier
DT Journal
LA English
CC 1-11 (Pharmacology)
AB The effects of inhibitors of **nitric oxide synthase** (NOS) on opioid withdrawal signs e.g. wt. loss, diarrhea, wet-dog shakes, etc., were studied in rats that were made morphine-dependent by s.c. **implantation** of morphine pellets. The results indicated that the selective brain NOS inhibitor 7-nitroindazole is more effective in inhibiting the withdrawal signs than the 2 nonselective NOS inhibitors, L-NNA and L-NAME.
ST **nitric oxide synthase** inhibitor opioid withdrawal
IT Brain
Drug dependence
(inhibitors of brain **nitric oxide synthase** as potential treatments for opioid withdrawal)
IT Opioids
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(inhibitors of brain **nitric oxide synthase** as potential treatments for opioid withdrawal)
IT 57-27-2, Morphine, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(inhibitors of brain **nitric oxide synthase** as potential treatments for opioid withdrawal)
IT 2149-70-4, L-NG-Nitroarginine 2942-42-9, 7-Nitroindazole **50903-99-6**, L-NAME

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of brain **nitric oxide synthase** as potential treatments for opioid withdrawal)

IT 125978-95-2, **Nitric oxide synthase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitors; inhibitors of brain **nitric oxide synthase** as potential treatments for opioid withdrawal)

```
=> e contraception
E1            1     CONTRACEPTINES/BI
E2            2     CONTRACEPTING/BI
E3         2635 --> CONTRACEPTION/BI
E4            1     CONTRACEPTIONAL/BI
E5            2     CONTRACEPTIONS/BI
E6            1     CONTRACEPTIV/BI
E7            2     CONTRACEPTIVA/BI
E8        10643     CONTRACEPTIVE/BI
E9           11     CONTRACEPTIVELY/BI
E10       12642     CONTRACEPTIVES/BI
E11           1     CONTRACEPTIVITY/BI
E12           1     CONTRACEPTORS/BI

=> s e3-e10
          2635 CONTRACEPTION/BI
             1 CONTRACEPTIONAL/BI
             2 CONTRACEPTIONS/BI
             1 CONTRACEPTIV/BI
             2 CONTRACEPTIVA/BI
         10643 CONTRACEPTIVE/BI
            11 CONTRACEPTIVELY/BI
         12642 CONTRACEPTIVES/BI
L21      14591 (CONTRACEPTION/BI OR CONTRACEPTIONAL/BI OR CONTRACEPTIONS/BI OR
               CONTRACEPTIV/BI OR CONTRACEPTIVA/BI OR CONTRACEPTIVE/BI OR CONTR
               ACEPTIVELY/BI OR CONTRACEPTIVES/BI)

=> s l21 and l13
L22           3 L21 AND L13

=> d l22 1-3

L22  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:869589  CAPLUS
DN   137:346927
TI   Implantation rates after in vitro fertilization, and treatment of
     infertility and early pregnancy loss with a nitric oxide donor or
     substrate alone or in combination with progesterone, and a method for
     contraception with nitric oxide inhibitors in combination with
     antiprogestins or other agents
IN   Chwalisz, Krzysztof; Garfield, Robert E.
PA   Germany
SO   U.S. Pat. Appl. Publ., 15 pp., Division of U.S. Ser. No. 162,446.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   US 2002169205       A1   20021114      US 2002-43232    20020114
```

PRAI US 1998-162446 A3 19980929

L22 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1999:203927 CAPLUS
DN 131:39874
TI Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat
AU Chwalisz, Kristof; Winterhager, Elke; Thienel, Thomas; Garfield, Robert E.
CS Research Laboratories of Schering AG, Berlin, 13342, Germany
SO Human Reproduction (1999), 14(2), 542-552
CODEN: HUREEE; ISSN: 0268-1161
PB Oxford University Press
DT Journal
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1995:795168 CAPLUS
DN 123:189355
TI Ovulation control by regulating nitric oxide levels
IN Garfield, Robert E.; Yallampalli, Chandrasekhar
PA Board of Regents, University of Texas System, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515753	A1	19950615	WO 1994-US14133	19941208
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5470847	A	19951128	US 1993-165309	19931210
	AU 9513041	A1	19950627	AU 1995-13041	19941208
	US 5643944	A	19970701	US 1995-477189	19950607
	US 5721278	A	19980224	US 1995-477187	19950607
PRAI	US 1993-165309		19931210		
	WO 1994-US14133		19941208		

=> d l22 3 all

L22 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1995:795168 CAPLUS
DN 123:189355
TI Ovulation control by regulating nitric oxide levels
IN Garfield, Robert E.; Yallampalli, Chandrasekhar
PA Board of Regents, University of Texas System, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-195
CC 2-3 (Mammalian Hormones)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9515753 A1 19950615 WO 1994-US14133 19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 5470847 A 19951128 US 1993-165309 19931210
AU 9513041 A1 19950627 AU 1995-13041 19941208
US 5643944 A 19970701 US 1995-477189 19950607
US 5721278 A 19980224 US 1995-477187 19950607
PRAI US 1993-165309 19931210
WO 1994-US14133 19941208

AB Inhibition of ovulation in a female may be achieved by administering a nitric oxide synthase inhibitor, alone or in combination with one or more of a progestin, an estrogen, and an LH-RH antagonist, thereby preventing conception. The stimulation of ovulation in a female may be achieved by administering a nitric oxide source, optionally in further combination with one or more of clomiphene, a gonadotropin, and an LH-RH agonist. Thus, 27 days old immature rats were injected with 4 IU of pregnant mare's serum gonadotropin on day on. Two days later rats were injected with 40 mg of NG-nitro-L-arginine Me ester at 12 AM and 3 PM and animals were sacrificed one day later and examd. for the ovulatory response by counting the no. of Graafian follicles 3 and corpora lutea 5 in the ovaries. The no. of Graffian follicles and corpora lutea was 9.7 and 0.7 resp. as compared to 1.0 and 10.0 for the controls.

ST ovulation control nitric oxide synthase inhibition; conception prevention nitric oxide synthase inhibition

IT **Contraceptives**
Insemination, artificial
Ovarian cycle
Ovulation
Pituitary gland
(ovulation control by regulating nitric oxide levels)

IT Estrogens
Gonadotropins
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ovulation control by regulating nitric oxide levels)

IT Fertilization
(extracorporeal, ovulation control by regulating nitric oxide levels)

IT Gonadotropins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, ovulation control by regulating nitric oxide levels)

IT 9034-40-6, GnRH 103733-02-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; ovulation control by regulating nitric oxide levels)

IT 50-28-2, 17.beta.-Estradiol, biological studies 50-50-0, Estradiol benzoate 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 57-83-0, Progesterone, biological studies 68-23-5, Norethinodrel 74-79-3, L-Arginine, biological studies 87-33-2, Isosorbide dinitrate 434-22-0, 19-Nortestosterone 520-85-4, Medroxyprogesterone 911-45-5, Clomiphene 2149-70-4 6533-00-2, Norgestrel 9002-67-9, LH 9034-40-6D, Lh-rh, analogs 14402-89-2, Sodium nitroprusside 16051-77-7, Isosorbide mononitrate 17035-90-4 17230-88-5, Danazol 20933-81-7 34973-08-5, Gonadorelin acetate 35189-28-7, Norgestimate **50903-99-6** 54024-22-5, Desogestrel 57444-72-1 60282-87-3, Gestodene 74381-53-6, Leuprolide acetate 76932-60-0, Nafarelin acetate 125978-95-2, Nitric oxide synthase 137361-05-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ovulation control by regulating nitric oxide levels)

=>

=> d his

(FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003)

FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
L1 4 S NAME
L2 5 S MIFEPRISTONE
L3 0 S ORG31710
L4 0 S ORG 3171-
L5 1 S ORG 31710
L6 1 S L5
L7 1 S L5
L8 1 S ORG 33628
L9 1 S J 867
L10 1 S CDB 2914
L11 1 S ZK 137316

FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
L12 21216 S NITRIC OXIDE SYNTHASE
L13 1379 S L1
E FERTILITY
L14 27611 S E3
L15 6 S L14 AND L13
L16 23 S L14 AND L12
L17 18 S L16 NOT L15
E IMPLANTATION
L18 78734 S E3
L19 99 S L18 AND L12
L20 5 S L19 AND L13
E CONTRACEPTION
L21 14591 S E3-E10
L22 3 S L21 AND L13

=> s l2
L23 1816 L2

=> s l23 and l21
L24 188 L23 AND L21

=> d l24 170-188

L24 ANSWER 170 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1988:738 CAPLUS
DN 108:738
TI Effects of RU38486, an antiprogesterone agent, on endometrium, fertilized ovum and serum sex steroid levels in rats
AU Ohtani, Kaori; Sakamoto, Hideki; Takahashi, Toru; Satoh, Nobuyoshi; Den, Konbai; Takagi, Shigeo
CS Sch. Med., Nihon Univ., Tokyo, Japan
SO Nippon Sanka Fujinka Gakkai Zasshi (1987), 39(10), 1709-14
CODEN: NISFAY; ISSN: 0300-9165
DT Journal
LA Japanese

L24 ANSWER 171 OF 188 CAPLUS COPYRIGHT 2003 ACS

AN 1987:629242 CAPLUS
DN 107:229242
TI Contragestion by the progesterone antagonist RU 486: a novel approach to human fertility control
AU Baulieu, Etienne Emile
CS Lab. Horm., Fac. Med., Bicetre, 94275, Fr.
SO Contraception (1987), 36(Suppl.), 1-5
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal; General Review
LA English

L24 ANSWER 172 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:547556 CAPLUS
DN 107:147556
TI Interception. III: Postcoital luteal contragestion by an antiprogestin (mifepristone, RU 486) in 62 women
AU Van Santen, M. R.; Haspels, A. A.
CS Dep. Obstet. Gynecol., Utrecht Univ. Hosp., Utrecht, Neth.
SO Contraception (1987), 35(5), 423-31
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L24 ANSWER 173 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:527350 CAPLUS
DN 107:127350
TI Interception. IV: Failure of mifepristone (RU 486) as a monthly contragestive, "Lunarette"
AU Van Santen, M. R.; Haspels, A. A.
CS Dep. Obstet. Gynecol., Utrecht Univ. Hosp., Utrecht, Neth.
SO Contraception (1987), 35(5), 433-8
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L24 ANSWER 174 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:509393 CAPLUS
DN 107:109393
TI Contragestion by antiprogestin RU 486: a novel approach to human fertility control
AU Baulieu, E. E.; Ulmann, A.; Philibert, D.
CS Lab-Hormones, Univ. Paris-Sud, Bicetre, 94275, Fr.
SO Serono Symposia Publications from Raven Press (1987), 36(Fertil. Regul. Today Tomorrow), 55-73
CODEN: SPRPDU; ISSN: 0733-897X
DT Journal; General Review
LA English

L24 ANSWER 175 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:423577 CAPLUS
DN 107:23577
TI Preparation of estradienolone derivatives useful as antiglucocorticoids and antiprogestomimetics,and their pharmaceutical formulation
IN Torelli, Vesperto; Teutsch, Jean G.; Philibert, Daniel
PA Roussel-UCLAF , Fr.
SO U.S., 41 pp. Cont.-in-part of U.S. 4,519,946.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 4634695	A	19870106	US 1985-693682	19850122
	FR 2497807	A1	19820716	FR 1981-272	19810109
	FR 2497807	B1	19830729		
	US 4386085	A	19830531	US 1982-338077	19820108
	US 4447424	A	19840508	US 1982-386967	19820610
	US 4519946	A	19850528	US 1984-614440	19840525
	US 4978657	A	19901218	US 1985-810316	19851217
	US 5043332	A	19910827	US 1989-421526	19891013
PRAI	FR 1981-272		19810109		
	US 1982-338077		19820108		
	US 1982-386967		19820610		
	US 1984-595267		19840330		
	US 1984-614440		19840525		
	FR 1982-10205		19820611		
	FR 1982-70205		19820611		
	US 1983-501373		19830606		
	US 1985-693682		19850122		
	US 1985-760703		19850730		
	US 1985-810316		19851217		

L24 ANSWER 176 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:113695 CAPLUS
DN 106:113695
TI The progesterone antagonist RU 486. A potential new **contraceptive** agent
AU Nieman, Lynnette K.; Choate, Teresa M.; Chrousos, George P.; Healy, David L.; Morin, Martin; Renquist, David; Merriam, George R.; Spitz, Irving M.; Bardin, C. Wayne; et al.
CS Dev. Endocrinol. Branch, Natl. Inst. Child Health Hum. Dev., Bethesda, MD, USA
SO New England Journal of Medicine (1987), 316(4), 187-91
CODEN: NEJMAG; ISSN: 0028-4793
DT Journal
LA English

L24 ANSWER 177 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1987:78799 CAPLUS
DN 106:78799
TI Fertility control in women: results with RU 486 by the end of 1985
AU Baulieu, Etienne
CS Lab. Horm., INSERM U33, Bicetre, 94275, Fr.
SO Journal of Steroid Biochemistry (1986), 25(5B), 847-51
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal; General Review
LA English

L24 ANSWER 178 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:565206 CAPLUS
DN 105:165206
TI Studies on the antireproductive mechanisms of action of RU 486
AU Rojas, Francisco J.; O'Conner, James L.; Asch, Ricardo H.
CS Health Sci. Cent., Univ. Texas, San Antonio, TX, USA
SO Antiprogestin Steroid RU 486 Hum. Fertil. Control, [Proc. Conf. Antiprogestational Compd. RU 486] (1985), Meeting Date 1984, 141-54. Editor(s): Baulieu, Etienne-Emile; Segal, Sheldon Jerome. Publisher: Plenum, New York, N. Y.
CODEN: 55DHAY
DT Conference
LA English

L24 ANSWER 179 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:565028 CAPLUS

DN 105:165028
TI RU 486: an antiprogestin steroid with contragestive activity in women
AU Baulieu, Etienne Emile
CS Lab. Horm., Univ. Paris Sud, Bicetre, 94270, Fr.
SO Antiprogestin Steroid RU 486 Hum. Fertil. Control, [Proc. Conf. Antiprogestational Compd. RU 486] (1985), Meeting Date 1984, 1-25. Editor(s): Baulieu, Etienne-Emile; Segal, Sheldon Jerome. Publisher: Plenum, New York, N. Y.
CODEN: 55DHAY
DT Conference; General Review
LA English

L24 ANSWER 180 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:435637 CAPLUS
DN 105:35637
TI Antiprogesterone activity of RU 486 and its contragestive and other applications
AU Baulieu, E. E.; Ulmann, A.
CS Fac. Med., INSERM 33, Bicetre, 94275, Fr.
SO Human Reproduction (1986), 1(2), 107-10
CODEN: HUREEE; ISSN: 0268-1161
DT Journal; General Review
LA English

L24 ANSWER 181 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:219236 CAPLUS
DN 104:219236
TI Steroid antihormones: the antiprogesterone activity of RU 486 and its **contraceptive** and other uses.
AU Baulieu, Etienne Emile; Ulmann, Andre
CS Univ. Paris-Sud, Paris, Fr.
SO Bulletin de l'Academie Nationale de Medecine (Paris, France) (1985), 169(8), 1191-9
CODEN: BANMAC; ISSN: 0001-4079
DT Journal; General Review
LA French

L24 ANSWER 182 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:200466 CAPLUS
DN 104:200466
TI Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486
AU Tseng, Linda; Mazella, James; Sun, Boling
CS Sch. Med., State Univ. New York, Stony Brook, NY, 11794, USA
SO Endocrinology (1986), 118(4), 1312-18
CODEN: ENDOAO; ISSN: 0013-7227
DT Journal
LA English

L24 ANSWER 183 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1986:142404 CAPLUS
DN 104:142404
TI The antiprogesterone steroid RU-486 does not impair gonadotropin-stimulated luteal adenylyl cyclase activity or gonadotropin release by pituitary cells
AU Rojas, Francisco J.; O'Conner, James L.; Asch, Ricardo H.
CS Health Sci. Cent., Univ. Texas, San Antonio, TX, 78284, USA
SO Journal of Steroid Biochemistry (1985), 23(6A), 1053-8
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal
LA English

L24 ANSWER 184 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1985:589900 CAPLUS
DN 103:189900
TI Contragestion by antiprogestin: a new approach to human fertility control
AU Baulieu, Etienne Emile
CS Fac. Med. Bicetre, Univ. Paris Sud, Bicetre, 94270, Fr.
SO Ciba Foundation Symposium (1985), 115(Abortion), 192-210
CODEN: CIBSB4; ISSN: 0300-5208
DT Journal; General Review
LA English

L24 ANSWER 185 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1985:516457 CAPLUS
DN 103:116457
TI Pregnancy prevention by intravaginal delivery of a progesterone antagonist: RU486 tampon for menstrual induction and absorption
AU Hodgen, Gary D.
CS Jones Inst. Reprod. Med., East. Virginia Med. Sch., Norfolk, VA, 23507, USA
SO Fertility and Sterility (1985), 44, 263-7
CODEN: FESTAS; ISSN: 0015-0282
DT Journal
LA English

L24 ANSWER 186 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1985:481878 CAPLUS
DN 103:81878
TI The antiprogesterone activity of RU 486, a contragestive agent in the human
AU Sakiz, E.; Euvrard, C.; Baulieu, E. E.
CS Roussel-Uclaf, Paris, 75007, Fr.
SO International Congress Series (1984), 655(Endocrinology), 239-42
CODEN: EXMDA4; ISSN: 0531-5131
DT Journal
LA English

L24 ANSWER 187 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1985:215412 CAPLUS
DN 102:215412
TI The effects of RU486 on the luteal phase of the rhesus monkey
AU Asch, Ricardo H.; Rojas, Francisco J.
CS Health Sci. Cent., Univ. Texas, San Antonio, TX, 78284, USA
SO Journal of Steroid Biochemistry (1985), 22(2), 227-30
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal
LA English

L24 ANSWER 188 OF 188 CAPLUS COPYRIGHT 2003 ACS
AN 1984:530975 CAPLUS
DN 101:130975
TI Steroid derivatives
IN Teutsch, Jean G.; Costerousse, Germain; Philibert, Daniel; Deraedt, Roger
PA Roussel-UCLAF , Fr.
SO U.S., 33 pp. Cont.-in-part of U.S. 4,386,085.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4447424	A	19840508	US 1982-386967	19820610
	FR 2497807	A1	19820716	FR 1981-272	19810109

```
     FR 2497807         B1   19830729
     US 4386085         A    19830531       US 1982-338077   19820108
     US 4519946         A    19850528       US 1984-614440   19840525
     US 4634695         A    19870106       US 1985-693682   19850122
     US 4978657         A    19901218       US 1985-810316   19851217
     US 5043332         A    19910827       US 1989-421526   19891013
PRAI FR 1981-272               19810109
     US 1982-338077            19820108
     US 1982-386967            19820610
     FR 1982-10205             19820611
     FR 1982-70205             19820611
     US 1983-501373            19830606
     US 1984-595267            19840330
     US 1984-614440            19840525
     US 1985-693682            19850122
     US 1985-760703            19850730
     US 1985-810316            19851217


=>  d his

     (FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003)

     FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
L1             4 S NAME
L2             5 S MIFEPRISTONE
L3             0 S ORG31710
L4             0 S ORG 3171-
L5             1 S ORG 31710
L6             1 S L5
L7             1 S L5
L8             1 S ORG 33628
L9             1 S J 867
L10            1 S CDB 2914
L11            1 S ZK 137316

     FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
L12        21216 S NITRIC OXIDE SYNTHASE
L13         1379 S L1
               E FERTILITY
L14        27611 S E3
L15            6 S L14 AND L13
L16           23 S L14 AND L12
L17           18 S L16 NOT L15
               E IMPLANTATION
L18        78734 S E3
L19           99 S L18 AND L12
L20            5 S L19 AND L13
               E CONTRACEPTION
L21        14591 S E3-E10
L22            3 S L21 AND L13
L23         1816 S L2
L24          188 S L23 AND L21

=> d 124 188 all

L24  ANSWER 188 OF 188  CAPLUS  COPYRIGHT 2003 ACS
AN   1984:530975  CAPLUS
DN   101:130975
TI   Steroid derivatives
IN   Teutsch, Jean G.; Costerousse, Germain; Philibert, Daniel; Deraedt, Roger
PA   Roussel-UCLAF , Fr.
```

SO U.S., 33 pp. Cont.-in-part of U.S. 4,386,085.
CODEN: USXXAM
DT Patent
LA English
IC A01N045-00; A61K031-56
NCL 424238000
CC 32-5 (Steroids)
Section cross-reference(s): 1, 2
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4447424	A	19840508	US 1982-386967	19820610
	FR 2497807	A1	19820716	FR 1981-272	19810109
	FR 2497807	B1	19830729		
	US 4386085	A	19830531	US 1982-338077	19820108
	US 4519946	A	19850528	US 1984-614440	19840525
	US 4634695	A	19870106	US 1985-693682	19850122
	US 4978657	A	19901218	US 1985-810316	19851217
	US 5043332	A	19910827	US 1989-421526	19891013

PRAI FR 1981-272 19810109
US 1982-338077 19820108
US 1982-386967 19820610
FR 1982-10205 19820611
FR 1982-70205 19820611
US 1983-501373 19830606
US 1984-595267 19840330
US 1984-614440 19840525
US 1985-693682 19850122
US 1985-760703 19850730
US 1985-810316 19851217

GI



I



II



III

AB Antiglucocorticoid and **contraceptive** norsteroids I [RR1 = O, ketal, HON:, CH2:; R = HO, alkoxy, acyloxy, R1 = H; R2R3 = O, bond; R4 = N-, P- or Si-contg. radical, i.e. pyridyl, dimethylaminoalkyl, 4-(Me2NCH2CH2O)C6H4, pyrrolidinophenyl, etc.; R5 = C1-C8 alkyl; R6, R7 = H, HO, alkoxy, acyloxy, HOCH2CO, HO2CCO, alkylcarbamoyl, etc.; R8, R9 =

HO, H, alkyl aralkyl; n = 1, 2; optional 16-unsatd.] were prepd. by ring cleavage of epoxyestrene derivs. by Grignard reagents. Thus, treatment of epoxypropynylestrene II with 4-(Me2N)C6H4MgBr in THF contg. CuBr-Me2S complex and subsequent acid hydrolysis gave (aminophenyl)propynylestradien e III. At 10 mg/kg/day for 3 days in female rats III inhibited implantation 100g, whereas at 500 .mu.g/animal in the rabbit III was devoid of progestomimetic activity.

ST aminophenylestradienone prepn **contraceptive**; estradienone aminophenyl prepn **contraceptive**; epoxyestrenol ring cleavage Grignard reagent; antiglucocorticoide estradienone

IT Abortion
(by nitrogen-contg. radical substituted estradienones)

IT Androgens
Progestogens
RL: USES (Uses)
(inhibitors, nitrogen-contg. radical substituted estradienones)

IT **Contraceptives**
(nitrogen-contg. radical substituted estradienones)

IT 19-Norsteroids
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, of nitrogen-contg. radical substituted estradienones)

IT 106-95-6, reactions 109-54-6 586-77-6 626-61-9 1066-54-2 2052-06-4 2474-07-9 6274-57-3 6999-03-7 16518-62-0 22090-26-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(Grignard ring cleavage reaction of, with epoxyestrenol deriv.)

IT 91935-18-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(Grignard ring cleavage reaction of, with epoxyetrenol deriv.)

IT 78-80-8 463-49-0 536-74-3 591-51-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(addn. reaction of, with (aminophenyl)estrenone deriv.)

IT 74-99-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(addn. reaction of, with estradienone deriv.)

IT 5571-36-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(addn. reaction of, with propyne)

IT 100-61-8, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of, by isoamyl bromide)

IT 91-66-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)

IT 79-01-6, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(dechlorination and addn. reaction with (aminophenyl)estrenone deriv.)

IT 91934-73-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(epimerization of)

IT 33403-21-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(epoxide ring cleavage of, with aminophenylmagnesium bromide deriv.)

IT 90944-65-3P 91935-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and Grignard ring cleavage reaction of, with epoxyestrenol deriv.)

IT 91934-77-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and addn. reaction of, with phenyllithium)

IT **84371-65-3P** 91934-81-5P 91934-84-8P 91934-85-9P

91934-86-0P 91934-89-3P 91935-00-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiglucocorticoid and **contraceptive** activities of)

IT 91934-93-9P 91934-98-4P 91984-11-1P 92009-03-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiglucocorticoid and **contraceptive** activity of)

IT 91935-09-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromination of)

IT 39931-87-8P 91934-74-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and epoxide ring cleavage of, by Grignard reagents)

IT 84371-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and epoxide ring cleavage reactions of, with Grignard reagents)

IT 84371-69-7P 92009-02-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and epoxidn. of)

IT 91935-04-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrogenation of)

IT 84371-60-8P 84371-62-0P 84371-64-2P 89359-46-6P 91934-71-3P
91934-75-7P 91934-78-0P 91934-80-4P 91934-83-7P 91934-88-2P
91934-90-6P 91934-91-7P 91934-95-1P 91934-96-2P 91934-99-5P
91935-01-2P 91935-03-4P 91935-05-6P 91935-07-8P 91935-11-4P
91935-13-6P 91935-15-8P 91935-19-2P 93790-79-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

IT 91934-94-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with lithium acetylide complex)

IT 84371-58-4P 84371-59-5P 84371-61-9P 84371-63-1P 84371-67-5P
84395-11-9P 89328-06-3P 91934-72-4P 91934-76-8P 91934-79-1P
91934-82-6P 91934-87-1P 91934-92-8P 91934-97-3P 91935-02-3P
91935-06-7P 91935-08-9P 91935-12-5P 91935-14-7P 91935-16-9P
91935-17-0P 91935-20-5P 91935-21-6P 91935-22-7P 91935-23-8P
91935-24-9P 91935-25-0P 91935-26-1P 91935-27-2P 91935-28-3P
91935-29-4P 91935-30-7P 91935-31-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 39990-99-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with cyanoestrenol deriv.)

IT 4584-46-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution reaction of, with bromothiophenol)

IT 106-53-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution reaction of, with dimethylaminoethyl chloride)

IT 107-82-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution reaction of, with methylaniline)

```
=>  d his

     (FILE 'HOME' ENTERED AT 15:25:42 ON 16 APR 2003)

     FILE 'REGISTRY' ENTERED AT 15:25:51 ON 16 APR 2003
L1             4 S NAME
L2             5 S MIFEPRISTONE
L3             0 S ORG31710
L4             0 S ORG 3171-
L5             1 S ORG 31710
L6             1 S L5
L7             1 S L5
L8             1 S ORG 33628
L9             1 S J 867
L10            1 S CDB 2914
L11            1 S ZK 137316

     FILE 'CAPLUS' ENTERED AT 15:30:05 ON 16 APR 2003
L12        21216 S NITRIC OXIDE SYNTHASE
L13         1379 S L1
                E FERTILITY
L14        27611 S E3
L15            6 S L14 AND L13
L16           23 S L14 AND L12
L17           18 S L16 NOT L15
                E IMPLANTATION
L18        78734 S E3
L19           99 S L18 AND L12
L20            5 S L19 AND L13
                E CONTRACEPTION
L21        14591 S E3-E10
L22            3 S L21 AND L13
L23         1816 S L2
L24          188 S L23 AND L21

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             151.26     246.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -8.46      -8.46

STN INTERNATIONAL LOGOFF AT 16:30:24 ON 16 APR 2003
```